Back to Search
Start Over
Magnesium Isoglycyrrhizinate Reduces Hepatic Lipotoxicity through Regulating Metabolic Abnormalities.
- Source :
-
International journal of molecular sciences [Int J Mol Sci] 2021 May 30; Vol. 22 (11). Date of Electronic Publication: 2021 May 30. - Publication Year :
- 2021
-
Abstract
- The excessive accumulation of lipids in hepatocytes induces a type of cytotoxicity called hepatic lipotoxicity, which is a fundamental contributor to liver metabolic diseases (such as NAFLD). Magnesium isoglycyrrhizinate (MGIG), a magnesium salt of the stereoisomer of natural glycyrrhizic acid, is widely used as a safe and effective liver protectant. However, the mechanism by which MGIG protects against NAFLD remains unknown. Based on the significant correlation between NAFLD and the reprogramming of liver metabolism, we aimed to explore the beneficial effects of MGIG from a metabolic viewpoint in this paper. We treated HepaRG cells with palmitic acid (PA, a saturated fatty acid of C16:0) to induce lipotoxicity and then evaluated the antagonistic effect of MGIG on lipotoxicity by investigating the cell survival rate, DNA proliferation rate, organelle damage, and endoplasmic reticulum stress (ERS). Metabolomics, lipidomics, and isotope tracing were used to investigate changes in the metabolite profile, lipid profile, and lipid flux in HepaRG cells under different intervention conditions. The results showed that MGIG can indeed protect hepatocytes against PA-induced cytotoxicity and ERS. In response to the metabolic abnormality of lipotoxicity, MGIG curtailed the metabolic activation of lipids induced by PA. The content of total lipids and saturated lipids containing C16:0 chains increased significantly after PA stimulation and then decreased significantly or even returned to normal levels after MGIG intervention. Lipidomic data show that glycerides and glycerophospholipids were the two most affected lipids. For excessive lipid accumulation in hepatocytes, MGIG can downregulate the expression of the metabolic enzymes (GPATs and DAGTs) involved in triglyceride biosynthesis. In conclusion, MGIG has a positive regulatory effect on the metabolic disorders that occur in hepatocytes under lipotoxicity, and the main mechanisms of this effect are in lipid metabolism, including reducing the total lipid content, reducing lipid saturation, inhibiting glyceride and glycerophospholipid metabolism, and downregulating the expression of metabolic enzymes in lipid synthesis.
- Subjects :
- Cell Line, Tumor
Cell Survival drug effects
Diacylglycerol O-Acyltransferase antagonists & inhibitors
Diacylglycerol O-Acyltransferase genetics
Diacylglycerol O-Acyltransferase metabolism
Endoplasmic Reticulum Stress drug effects
Gene Expression Regulation
Glycerides classification
Glycerides metabolism
Glycerol-3-Phosphate O-Acyltransferase antagonists & inhibitors
Glycerol-3-Phosphate O-Acyltransferase genetics
Glycerol-3-Phosphate O-Acyltransferase metabolism
Glycerophospholipids classification
Glycerophospholipids metabolism
Hepatocytes metabolism
Hepatocytes pathology
Humans
Lipid Metabolism genetics
Lipidomics
Palmitic Acid toxicity
Hepatocytes drug effects
Lipid Metabolism drug effects
Metabolome drug effects
Palmitic Acid antagonists & inhibitors
Protective Agents pharmacology
Saponins pharmacology
Triterpenes pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1422-0067
- Volume :
- 22
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- International journal of molecular sciences
- Publication Type :
- Academic Journal
- Accession number :
- 34070938
- Full Text :
- https://doi.org/10.3390/ijms22115884